Precision Cancer Medicine Program
At UCSF, we believe cancer therapy works best when it's tailored to the patient. Our Pediatric Precision Cancer Medicine Program makes this personalized care possible for children, teens and young adults with any kind of cancer, including cancers that are rare, high-risk or resistant to standard therapies.
Our team uses leading-edge tools, such as the UCSF500 Cancer Gene Panel, to identify the genetic signatures of a patient's disease. These findings can help us diagnose cancers more precisely and allow us to design personalized treatment plans that maximize effectiveness while minimizing side effects. We also work alongside other UCSF specialists to make sure all our patients receive care that's comprehensive, top-notch and compassionate.
What's more, our doctors are leaders in national research groups dedicated to childhood cancers, including leukemia, neuroblastoma and pediatric brain tumors. This means our patients can access treatments that are still being tested in clinical trials. We're the only Northern California hospital that's part of the National Cancer Institute's Pediatric Early Phase Clinical Trials Network, a small group of top institutions tasked with developing new therapies for cancers affecting kids.
Many of the precision cancer services we provide are not readily available at other hospitals, and some are offered only at UCSF. Yet patients who don't live near the Bay Area can still benefit from our expertise: We work with oncologists throughout the country and world to analyze tumor samples and guide treatments that can be administered by the patient's local care team.
Request appointment
To schedule an appointment with the Pediatric Precision Cancer Medicine Program, please give us a call at (415) 476-3831.
Please note that many insurance plans require a referral from your child's primary care physician before you schedule a visit at UCSF. We ask that you contact your insurance carrier to check if you need an authorization before your appointment. If a referral is required, please ask your child's primary care physician to fax a referral form and any applicable medical records to the UCSF Pediatric Access Center at (415) 353-4485.
Our locations (1)
Highlights of our cancer care
Leading-edge treatments
We're among the first to offer new treatment options, as soon as they're proven safe and effective. In addition, patients can access promising experimental therapies by participating in one of our many clinical trials.
Precision medicine
High-risk tumors are analyzed with the UCSF500 Cancer Gene Panel, a state-of-the-art test that identifies mutations in the tumor's DNA. The results can indicate the best treatment course and, in some cases, clarify the exact type of cancer.
Seamless care, near and far
Dedicated patient navigators help families with managing referrals, insurance concerns and appointment planning. We work with patients and referring doctors well beyond the San Francisco Bay Area, thanks to our comprehensive telehealth system.
Thorough follow-up
Our Pediatric Survivorship Program provides expert care to address any medical, psychological or social issues that arise after treatment is complete. The team also ensures smooth transitions to adult care providers as our patients leave childhood behind.
Our team
-
Anuradha Banerjee
MD, MPH
Pediatric neuro-oncologist -
Robert E. Goldsby
MD
Pediatric hematologist-oncologist -
Arun Rangaswami
MD
Pediatric hematologist-oncologist -
Alyssa Reddy
MD
Pediatric neurologist and neuro-oncologist -
Amit J. Sabnis
MD, MS
Pediatric hematologist-oncologist -
Helen Sang
OT
Occupational therapist -
Elliot Stieglitz
MD
Pediatric hematologist-oncologist -
Alejandro Sweet-Cordero
MD
Pediatric hematologist-oncologist -
Asmin Tulpule
MD
Pediatric hematologist-oncologist -
Kieuhoa T. Vo
MD, MAS
Pediatric hematologist-oncologist
Awards & recognition
-
Best in Northern California for cancer care
-
Ranked among the nation's best in 11 specialties
-
Designated an early phase clinical trials core site by the Children's Oncology Group
Plan your visit
What to Bring
- Photo I.D.
- Health insurance card
- Insurance authorization, if required
- Doctor's referral, if required
- Recent test results related to your child's condition
- List of medications, including dosages, plus any your child is allergic to
- List of questions you may have
- Device or paper for taking notes
Related clinics (5)
Blood & Marrow Transplant (BMT) Clinic
Pediatric Hereditary Cancer Clinic
General Surgery Clinic
Orthopedic Surgical Oncology Clinic
Support services
Clinical trials
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL...
Improvement in 5-year disease-free survival (DFS) with modified Berlin-Frankfurt-Münster (mBFM) chemotherapy without delayed intensification (DI) part 2 but with inotuzumab ozogamicin, versus full mBFM chemotherapy backbone includ...
Recruiting
More about this studyTegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and D...
The number of patients experiencing a cycle 1 dose limiting toxicity at least possibly attributable to tegavivint by study part and dose level.
Recruiting
More about this studyA Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or R...
Regimen A Cycle 1 will be used for determination of recommended phase 2 dose (RP2D)-lymphoid (L) directed chemotherapy block. A patient will be considered as being evaluable for DLT if: (1) the patient receives at least 66 doses o...
Recruiting
More about this studyCBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymp...
Maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of CBL0137 in children with relapsed or refractory solid tumors including CNS tumors and lymphoma.
Recruiting
More about this studyThe Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in...
The proportion will be calculated as the percent of eligible patients who are identified to have an a priori specified genomic or immunophenotypic target and who enroll on at least one of the sub-trials. The corresponding confiden...
Recruiting
More about this studyA Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine f...
Frequency percent (%) of patients with acute myeloid leukemia (AML) in second or greater relapse or refractory to relapse therapy who experience a cycle 1 dose limiting toxicity to imetelstat administered in combination with fluda...
Recruiting
More about this studyTiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Def...
Frequency (%) of pediatric patients (<18 years) with cycle 1 dose limiting toxicities attributable to tiragolumab as monotherapy in the safety cohort (Part A).
Recruiting
More about this studyInotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or...
The response rate will be estimated using the proportion of eligible/evaluable patients with CR/CRi response. A one-sided lower 95% Agresti-Coull confidence limit will be calculated.
Recruiting
More about this studyVincristine Pharmacokinetics in Infants
Estimate (95% CI) of the mean area under the concentration time curve for the elimination phase assessed at 0, 2, 6-8, and 18-24 hours after vinCRISTine dose by age group.
Recruiting
More about this studyOlaparib With Ceralasertib in Recurrent Osteosarcoma
Simon's two-stage design will be applied to the primary (binary) endpoint, event-free at 4-months. An event is defined as the occurrence of relapse, disease progression as defined by RECIST 1.1, or death from any cause.
Recruiting
More about this studyOur research initiatives
Smell the roses